Sign In
Buy LIXT
$7.48
-0.130 (-1.71%)
At Close: Jun 22, 2026
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
08:30am, Thursday, 18'th Jun 2026
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol BOCA RA
The New Bottleneck Isn’t Computing Power — It’s Just Power
10:45am, Friday, 12'th Jun 2026
Issued on behalf of LIXTE Biotechnology Holdings, Inc. America can build data centers in months, but the electricity to run them can take half a decade to arrive. That gap is becoming one of the bigge
Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity
Announcement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Decade Energy and Infrastructure Investor — to the Company's Board of Directors
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastr
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
05:18pm, Thursday, 14'th May 2026
BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
08:00am, Monday, 13'th Apr 2026
-Trial Combines LIXTE's LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options-
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
03:45pm, Tuesday, 31'st Mar 2026
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused
Powell Max Limited Successfully Repositions for Its Next Phase of Growth
08:30am, Monday, 09'th Mar 2026
Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (Nasdaq: PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following c
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
08:00am, Wednesday, 18'th Feb 2026
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused o
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
08:00am, Wednesday, 21'st Jan 2026
Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
08:00am, Tuesday, 20'th Jan 2026
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a fi
Lixte Biotechnology (NASDAQ:LIXT) Trading Up 0.5% – Here’s Why
02:07am, Saturday, 27'th Dec 2025
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT - Get Free Report)'s share price traded up 0.5% during trading on Friday. The stock traded as high as $4.14 and last traded at $4.07. 38,006 shares cha
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
08:00am, Tuesday, 23'rd Dec 2025
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc
New York, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, announces its role as exclusive placement agent in a $4. 3 million registered direct
